Retrospective Validation of Clinical Decision Support Tools for Predicting Effectiveness Outcomes in Inflammatory Bowel Disease Patients Treated with Vedolizumab.

ABSTRACT: Background/Objectives: Two clinical decision support tools (CDSTs) have been developed to predict treatment effectiveness of vedolizumab in Crohn's disease (CD) and ulcerative colitis (UC). This study aimed to validate the CDSTs with real-world data from a Dutch teaching hospital. Methods: Patients with CD or UC treated with vedolizumab between October 2014 and July 2023 were included. IBD patients treated with ustekinumab were included to study the specificity of the CDSTs. The primary outcomes were rates of clinical remission (CREM), biochemical remission (BioREM), composite (either clinical or biochemical) remission (CompREM) and corticosteroid-free clinical remission (CSF-CREM) at week 14, 30 and 54. Results: 32 CD patients and 41 UC patients treated with vedolizum

SUBMITTER: de Klaver PAG 

PROVIDER: S-EPMC12845096 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature